Emergent BioSolutions, a specialty pharmaceutical company and contract manufacturing organization, has completed its acquisition of GlaxoSmithKline’s raxibacumab, a fully human monoclonal antibody approved by the US Food and Drug Administration for the treatment and prophylactic treatment for inhalational anthrax.

With the acquisition, Emergent also plans to assume responsibility for a multi-year contract with the Biomedical Advanced Research and Development Authority, which is part of Office of the Assistant Secretary for Preparedness and Response in the US Department of Health and Human Services, valued at up to approximately $130 million to supply the product to the US Strategic National Stockpile through November 2019. The completion of the acquisition follows the satisfaction or waiver by the parties, as applicable, of all closing conditions, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

Source: Emergent Biosolutions